Actively Recruiting
Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
Led by University of Zurich · Updated on 2024-07-01
16
Participants Needed
1
Research Sites
177 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In vitro and in vivo data show promising results of adjunctive use of Chloroquine to standard tuberculosis therapy as Chloroquine enhances animicrobial effectiveness against intracellular MTB. To date, no safety data of the concurrent use of both treatments is availble. In a phase I trial, the investigators aim to evaluate safety and tolerability of the concurrent use of Chloroquine and standard anti-TB drug in healthy volunteers.
CONDITIONS
Official Title
Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent for the study and possible genetic analysis
- Healthy volunteers aged between 18 and 50 years
You will not qualify if you...
- Lack of highly effective contraception during treatment and for 8 months after last dose
- Pregnant or lactating females
- Known allergy or hypersensitivity to study drugs or glucose-6-phosphate dehydrogenase deficiency
- Use of regular medications in the 14 days before study start except Paracetamol and Vitamin B6
- History or presence of serious heart, immune, lung, nerve, kidney, digestive, skin, or hormone diseases
- Any significant abnormalities in vital signs, ECG, labs, or medical/psychiatric conditions interfering with study
- History or current retinal or vision problems
- Alcohol or substance abuse in the last 3 months
- Body weight less than 55 kg
- Intake of grapefruit or grapefruit juice within 2 weeks before and during treatment
- Blood donation within 30 days before screening
- Current or planned participation in other interventional clinical trials within 3 months
- Inability to follow study procedures due to language, psychological, or cognitive issues
- Investigator or their close associates are excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Trial Center
Zurich, Switzerland, 8091
Actively Recruiting
Research Team
K
Khadija M'Rabet, Dr. med.
CONTACT
J
Jean Marc Hoffmann, Dr med.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here